ReMogliflozin etabonate
ReMogliflozin etabonate Basic information
- Product Name:
- ReMogliflozin etabonate
- Synonyms:
-
- ReMogliflozin etabonate
- ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate
- GSK 189075
- ethyl(((2R,3S,4S,5R,6S)-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)-3,4,5-tri(l1-oxidanyl)tetrahydro-2H-pyran-2-yl)methyl)carbonateGSK-189075
- EOS-61714
- UAOCLDQAQNNEAX-ABMICEGHSA-N
- β-D-Glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 6-(ethyl carbonate)
- GSK 189075A
- CAS:
- 442201-24-3
- MF:
- C26H38N2O9
- MW:
- 522.6
- Mol File:
- 442201-24-3.mol
ReMogliflozin etabonate Chemical Properties
- Boiling point:
- 661.3±55.0 °C(Predicted)
- Density
- 1.31±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: Soluble; Methanol: Soluble
- form
- A solid
- pka
- 12.58±0.70(Predicted)
- color
- White to off-white
- InChIKey
- UAOCLDQAQNNEAX-JJJFNNNPNA-N
- SMILES
- O([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O1)O)C1=NN(C(C)C)C(C)=C1CC1C=CC(OC(C)C)=CC=1 |&1:1,2,3,5,7,r|
ReMogliflozin etabonate Usage And Synthesis
Uses
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models[1].
Definition
ChEBI: Remogliflozin etabonate is a glycoside.
Synthesis
Synthesis of ReMogliflozin etabonate
in vivo
Remogliflozin etabonate (GSK189075; 10 or 30 mg/kg; orally; twice daily for 6 weeks) significantly reduced both the FPG and GHb levels in a dosedependent manner[1].
Remogliflozin etabonate (3, 10, 30 mg/kg; orally) increases urinary glucose excretion in a dose-dependent manner. Remogliflozin etabonate dose-dependently inhibits the increase in plasma glucose after glucose loading and decreases the plasma insulin in normal rats[1].
Remogliflozin etabonate (1-10 mg/kg; orally) decreases the blood glucose and reduces the AUC0–6 h for blood glucose in a dose-dependent manner[1].
Remogliflozin etabonate (high-fat diet containing 0.01, 0.03, or 0.1% remogliflozin etabonate for 8 weeks) reduces the levels of plasma glucose, plasma insulin, and GHb in a dose-dependent manner, and it suppresses the development of hypertriglyceridemia in male GK rats (6 weeks of age)[1].
| Animal Model: | db/db mice at the age of 8 weeks[1] |
| Dosage: | 10 or 30 mg/kg |
| Administration: | Orally; twice daily for 6 weeks |
| Result: | Significantly reduced both the fasting plasma glucose (FPG) and glycated hemoglobin (GHb) levels in a dosedependent manner. Reduced both urine volume and urinary glucose excretion with ameliorated the hyperglycemia. |
IC 50
hSGLT2: 1.95 μM (Ki); rSGLT2: 2.14 μM (Ki); hSGLT1: 43.1 μM (Ki); rSGLT1: 8.57 μM (Ki)
References
[1] Yoshikazu Fujimori, et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. DOI:10.1124/jpet.108.140210
ReMogliflozin etabonateSupplier
- Tel
- 0571-0571-28806358 15397199029
- songxy@doepharma.com
- Tel
- 021-50182298 021-50180596
- sales@boylechem.com
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
- Tel
- 0512-87182056 18013166090
- lingling.qi@yacoo.com.cn
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com